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Prostate cancer is a clinically heterogeneous and multifocal disease. More than 80% of patients with prostate cancer
harbor multiple geographically discrete cancer foci at the time of diagnosis. Emerging data suggest that these foci are
molecularly distinct consistent with the hypothesis that they arise as independent clones. One of the strongest
arguments is the heterogeneity observed in the status of E26 transformation specific (ETS) rearrangements between
discrete tumor foci. The clonal evolution of individual prostate cancer foci based on recent studies demonstrates
intertumoral heterogeneity with intratumoral homogeneity. The issue of multifocality and interfocal heterogeneity is
important and has not been fully elucidated due to lack of the systematic evaluation of ETS rearrangements in multiple
tumor sites. The current study investigates the frequency of multiple gene rearrangements within the same focus and
between different cancer foci. Fluorescence in situ hybridization (FISH) assays were designed to detect the four most
common recurrent ETS gene rearrangements. In a cohort of 88 men with localized prostate cancer, we found ERG, ETV1,
and ETV5 rearrangements in 51% (44/86), 6% (5/85), and 1% (1/86), respectively. None of the cases demonstrated ETV4
rearrangements. Mutual exclusiveness of ETS rearrangements was observed in the majority of cases; however, in six cases,
we discovered multiple ETS or 50 fusion partner rearrangements within the same tumor focus. In conclusion, we provide
further evidence for prostate cancer tumor heterogeneity with the identification of multiple concurrent gene
rearrangements.
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Prostate cancer is a clinically heterogeneous and multifocal
disease.
1,2 More than 80% of patients with prostate cancer
harbor multiple geographically discrete cancer foci at the
time of diagnosis.
3 Emerging molecular data suggest that
these foci are molecularly distinct consistent with them
arising as independent clones.
4 One of the strongest pieces
of data is the heterogeneity observed in the status of
E26 transformation specific (ETS) transcription factors
rearrangements between different foci. ETS rearrangements
occur early in the development of prostate cancer.
5 Although
a number of rearrangements involving different ETS genes
and different 50 fusion partners have been described,
6 the
fusion of ERG with the androgen-regulated TMPRSS2 gene is
the most common recurrent lesion in prostate cancer,
occurring in B45% of screened prostate cancers.
7 The clonal
evolution of individual prostate cancer foci based on
recent studies demonstrates intertumoral heterogeneity with
intratumoral homogeneity.
8–10 This supports the view that
these tumors developed separately or diverged molecularly
at an early time point.
8,10,11 When studying metastases
of men who died of castration-resistant prostate cancer,
Mehra et al
11 demonstrated the clonal expansion of tumors
to metastatic sites. Two recent studies further support this
concept by demonstrating that the metastases are more
consistent with clones than the heterogeneous population of
tumor cells.
12,13
The initial observation that ETS rearrangements are mu-
tually exclusive supports the hypothesis that the molecular
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14 However,
Clark et al
10 demonstrated an example of two ETS gene
rearrangements (ie ERG and ETV1) involving two separate
tumor foci from the same patient. Han et al
15 screened for 27
ETS genes and all known 50 fusion partners in a cohort
of 110 tumors from a prostatectomy series captured on a
tissue microarray (TMA). Besides identifying novel fusions
including SLC45A3-ERG and DDX5-ETV4, they further
identified three cases with TMPRSS2-ERG fusion and an
additional alteration with either the 50 or 30 end of another
ETS gene being deleted. This finding suggests that the rule
of mutual exclusiveness of ETS rearrangements may have
exceptions. Therefore, in order to test the rule of mutual
exclusiveness, we present a detailed analysis of four recurrent
ETS rearrangements in a US prostatectomy cohort.
MATERIALS AND METHODS
Cohort Description
The study cohort is comprised of 88 patients (mean age 63.2
years) who underwent radical prostatectomy at Weill Cornell
Medical College (New York, NY, USA) as a monotherapy. The
pathological stages ranged from organ confined to cases with
extraprostatic tumor extension. The prostate gland was
evaluated for discrete tumor foci. A prostate cancer sample
was considered multifocal if tumor nodules were identified
on contralateral sides of the gland. Ipsilateral tumor nodules
were defined as separated by a minimum of 3mm from the
nearest tumor nodule in any single section or by a minimum
of 4mm from the closest nodule on the adjacent section
above or below.
2,16 Tumor maps were generated by tracking
each section according to the pathology report and
reconstructing them in a whole-mount manner. Primary,
secondary, tertiary, and quaternary tumor foci from the
prostate were designated in decreasing order based on tumor
diameter (cm).
TMA Construction
Histologic examination of all tumor foci was performed by
the study pathologists. The pathologists circled representative
areas within each focus from which three 0.6mm cancer
cores were sampled for TMA construction. This resulted in a
TMA with representative tumor samples from each histolo-
gically discrete tumor focus identified for all of the prostate
cancer cases included in the study. The study was approved
by the Weill Cornell Medical College IRB.
Assessment of Gene Rearrangement Status by Dual-
Color Interphase Fluorescence In Situ Hybridization
Four-micron thick TMA sections were used for interphase
fluorescence in situ hybridization (FISH). Based on the sys-
tematic evaluation of 27 ETS rearrangements by Han et al,
15
we selected four ETS genes for evaluation: ERG, ETV1, ETV4,
and ETV5. We also chose four recurrent 50 fusion partners:
TMPRSS2, SLC45A3, NDRG1, and Herv-K22q11.23. The
following centromeric/telomeric BAC clones were used to
assess for rearrangement status: ERG (RP11-24A11 and
RP11-372O17), ETV1 (RP11-661L15 and RP11-79G16),
ETV5 (RP11-480B15 and RP11-822O23), ETV4 (CTP-
3215I16 and RP11-147C10), TMPRSS2 (RP11-35C4 and
RP11-120C17), SLC45A3 (RP11-249H15 and RP11-131E5),
NDRG1 (RP11-185E14 and RP11-1145H17), and Herv-
K22q11.23 (RP11-61N10 and RP11-71G19). Break apart
dual-color interphase FISH assay was performed as pre-
viously described,
5,14,17 as an approach to systematically
identify putative rearrangements. This FISH assay enables us
to distinguish between two different rearrangement me-
chanisms, rearrangement through insertion and rearrange-
ment through deletion as previously described. A nucleus
without a rearrangement demonstrates two pairs of juxta-
posed red and green signals (mostly forming two yellow
signals). A nucleus with rearrangement through insertion
shows the split of one red–green (yellow) signal pair, result-
ing in a single red and green signal for the rearranged allele,
and a still combined (yellow) signal for the non-rearranged
allele in each nucleus. Finally, a nucleus with a rearrangement
through deletion shows one juxtaposed red–green signal pair
(yellow) for the non-rearranged allele, and a single red signal
for the allele involved in the rearrangement. When finding
cases with multiple 50 or 30 rearrangements in a case on the
TMA, we went back to the tissue block that was used to
construct the TMA and performed fusion FISH to assess for
gene fusions, using differently labeled probes for each gene of
interest. When a fusion occurs, the signal patterns is opposite
from the break apart assay. In a fusion assay, the red–green
signal pair (yellow) is representing the two fused genes,
whereas the separate red and green signals represent the genes
that are not fused. The following probe combinations were
used for fusion FISH: RP11-131E5 and RP11-24A11
(SLC45A3-ERG fusion), RP11-131E5 and RP11-692L4
(SLC45A3-ETV1 fusion), RP11-35C4 and RP11-692L4
(TMPRSS2-ETV1 fusion), RP11-185E14 and RP11-372O17
(NDRG1-ERG fusion), and RP11-131E5 and RP11-480B15
(SLC45A3-ETV5 fusion). For each case, at least 100 cancer
nuclei were assessed, and a case was considered to be rear-
ranged if at least 20% of the nuclei assessed harbored a
rearrangement. With a minimum of 20% rearranged nuclei
as a cutoff for calling a case positive, we believe that we can
be certain that we are seeing an actual rearrangement event
and not an event due to artifacts that can be caused by the
thickness of the tissue section or overlapping nuclei. Per-
centages of rearrangements were evaluated by considering a
case positive if at least one focus was positive.
Four-Color Automated In Situ Hybridization
To be able to confirm co-occurring 50 gene rearrangements
within one nucleus, we applied the new four-color Quantum
dot (QD) technology in situ hybridization. With this tech-
nique, it is possible to multiplex the FISH assay by using four
differently labeled probes (QD) instead of the conventional
FISH, which have two differently labeled probes. All steps
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conducted on the BenchMark
sXT automated slide proces-
sing system (Ventana Medical Systems, Tucson, AZ, USA).
Unless otherwise, all reagents used in the automated four-
color in situ hybridization protocol are from Ventana. Briefly,
slides were deparaffinized using a combination of heat
(651C, 25min) and a mild detergent (EZ-Prep, Ventana) at
761C with eight washes for 1min each. Antigen retrieval was
conducted in the presence of heat (901C, 8min) and a serine
protease (0.02CU/ml, 12min). Genomic DNAwas denatured
online at 951C for 5min, followed by probe hybridization for
8h at 521C in Hybrizol. All four probes were simultaneously
applied as a cocktail at 8mg each per slide. Human placental
DNA (200mg per slide) was used to block repetitive DNA
sequences. BAC probes for 50 and 30 NDRG1, and 50 and 30
TMPRRS2 were labeled with the respective dNTP haptens
using random priming as described previously.
18 Specifically,
50 NDRG1 was labeled with dUTP biotin (Roche, Penzberg,
Germany), 30 NDRG1 with dUTP TS (thiazole sulfonamide)
(Ventana), 50 TMPRSS2 with amino dUTP DNP (Ventana),
and 30 TMPRSS2 with dUTP DIG (Roche). Detection
was conducted online as a part of the Benchmark
sXT
protocol with sAV QD625 (Life Technologies, OR, USA),
mouse monoclonal anti-TS (clone 13A06-01E11, Ventana)
conjugated to QD605, mouse monoclonal anti-DNP (clone
1C7-1C7, Ventana) conjugated to QD655, and with mouse
monoclonal anti-DIG (clone 1-171-256, Roche) conjugated
to QD565. All antibody conjugations were conducted using
30n PEGylated QD (Life Technologies) and purified mono-
clonal antibodies.
19 DAPI (Ventana) was also applied online
to counter-stain nuclei for imaging.
QD FISH image capture and analysis
Spectral image cubes containing high-resolution wavelength
intensity information at each pixel were captured using
a modified SpectraViewt acquisition and analysis system
(ASI; Applied Spectral Imaging, Israel). The modified system
comprises a computer workstation, fluorescent microscope
(Olympus BX61), a light-guide coupled, and stabilized metal
halide excitation source (Exfo Exacte, Exfo, Ontario, CA,
USA), with spectral output from an interferometer optical
head to a Sony ICX285 digital CCD.
20–23 The excitation/
emission filters for spectral imaging (Semrock, USA) were as
follows: 377nm center wavelength with 50nm bandwidth for
excitation; dichroic beamsplitter with reflection band below
410nm, and a long pass filter with deep blocking transition
at 409nm. All spectral image cubes were captured with a
 40 plan-fluor objective (numerical aperture 0.75) and  1
c-mount.
Data were gathered through a series of 100ms exposures to
build the interferometric image cube for spectral processing.
The wavelength range represented by image cubes captured
under these conditions covered the visible wavelengths
between 410 and 900nm at a 10-nm wavelength sampling
resolution. Spectral unmixing to separate signals correspond-
ing to tissue autofluorescence, DAPI, QD 565, QD 605, QD
625, and QD 655 was conducted using the appropriate re-
ference spectra and linear unmixing algorithms
24 implemented
in SpectraViewt spectral data analysis software (ASI). The
distinctive narrow Gaussian wavelength distribution and dis-
creet peak locations of the QD emission spectra enabled reli-
able separation of the individual probe signals. The individual
monochrome FISH signal intensity layers were colorized and
merged to provide overlay images for visualization of relative
probe localizations using Image-Pro Plus image analysis and
measurement software (Media Cybernetics, USA). For the
automated in situ hybridization, the same evaluation criteria
and cutoff were used as for the standard FISH assay (ie manual
assessment of a minimum of 100 nuclei/case with a re-
arrangement occurrence in a minimum of 20% of the assessed
nuclei to be called rearrangement positive).
Statistical Analysis
Within the set of cases with ERG, TMPRSS2, and SLC45A3
rearrangements, we investigated for significant association,
using Pearson w
2 test, between the different rearrangements
with Gleason grade and pathological stage. For the cases with
ERG rearrangements, we further distinguished between the
two types of rearrangement mechanisms (ie rearrangement
through insertion or deletion). A two-tailed P-value of r0.05
was considered significant. Given the number of samples
screened for rearrangement (n¼88), this study is powered to
detect rearrangements with incidence of 3.5% (P¼0.05).
Therefore, there is uncertainty when we found percent
incidence below 3.5%.
RESULTS
Frequency of Three Common ETS Gene Rearrangements
We evaluated 88 cases of localized prostate cancer for
rearrangements of the four recurrent ETS genes (Figure 1).
ERG, ETV1, and ETV5 were rearranged in 51% (44/86), 6%
(5/85), and 1% (1/86) of the cases, respectively. None of the
cases demonstrated rearrangement for ETV4 (Table 1). ERG
rearrangement through insertion was seen in 52% (23/44),
rearrangement through deletion in 39% (17/44). Interest-
ingly, four cases with multiple tumor foci demonstrated
rearrangement through insertion in one focus and re-
arrangement through deletion in the other focus (Figure 2).
Figure 1 Summary matrix of 50 gene fusion partners and ETS genes rearrangements investigated, sorted to show the rearranged cases first. Case
number, focus-specific subnumber, Gleason grade (pertaining to the core), and stage are indicated on the left. The subnumbers represent the different
tumor foci of the case. Color legend signifies respective aberration and availability. Rearrangement through insertion (T), rearrangement through
deletion (TþD), copy number increase (CNI).
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fusion partners TMPRSS2 and SLC45A3 were 43% (35/81) and
12% (10/86), respectively. None of the cases demonstrated
rearrangement for Herv-K22q11.23 (Table 1). We also found
the novel 50 fusion partner NDRG1
25 to be rearranged in 2%
(2/85) of the cases. Before starting with the FISH assessments,
we set a cutoff of a minimum of 20% rearranged nuclei to
call a case rearrangement positive. However, after evaluating
the cohort for the different gene rearrangements, we found
that in 95% of the cases, the rearrangements were seen in
450% of the evaluated nuclei. Based on our power calcu-
lations, the true incidence of the genes reported in this study
as not being rearranged can vary between 0 and 3.5% in the
population. We did not observe any statistically significant
associations between TMPRSS2-ERG and SLC45A3-ERG
rearrangements with Gleason grade or pathological stage. On a
subset of cases (37/88), we performed TMPRSS2-ERG fusion
transcript analysis with qRT–PCR and found that 35/37 cases
were in agreement with our FISH results (data not shown).
The two discrepant cases may be due to sampling where the
tissue cored for PCR was not directly adjacent to the tissue
used in the TMA. Alternatively, the PCR primers used do not
capture all TMPRSS2-ERG isoforms.
ETS Rearrangements in Cases of Multifocal Prostate
Cancer
Fifty-five percent (48/88) of the prostate cancer cases had
multiple, discrete tumor foci. We were able to assess 44/48 of
the cases for multifocal heterogeneity in all the genes
investigated in this study. Interfocal homogeneity was observed
in 24/44 cases (Figure 1), with 15 cases negative for all
gene rearrangements. Nine cases were positive for the same
gene rearrangements throughout all tumor foci. Of these nine
cases, six were positive for TMPRSS2-ERG rearrangement,
all through deletion mechanism. One case (#26) showed
TMPRSS2-ERG rearrangement with one focus rearranged
through deletion and the other focus rearranged through
insertion for both genes, respectively. Three cases showed
ETV1 rearrangement without any co-occurring rearrange-
ment of the 50 partners screened in this study, suggesting
another 50 partner. One of these cases (#49) harbored both
rearrangement through insertion in one focus and re-
arrangement through deletion in the other. The remaining 20
cases displayed interfocal heterogeneity.
From 88 cases, we observed TMPRSS2-ERG rearrangement
in at least one focus in 33 cases. Twenty-six of these cases
displayed a mutually exclusive pattern for only TMPRSS2 and
ERG rearrangement, with 35% (9/26) being rearranged
through insertion, 54% (14/26) through deletion, and 12%
(3/26) showing both rearrangement mechanisms. The
remaining seven cases showed at least one more gene
rearranged, in addition to TMPRSS2 and ERG (Table 2). This
co-occurrence of multiple gene rearrangements was seen in a
subset of the same cells in the tumor focus (Figure 3). Five of
these seven cases had a second 50 gene rearrangement along
with the ETS gene rearrangement in the same tumor focus
Table 1 Rearrangement frequencies are given in percentages (number of rearranged cases/evaluable cases), as shown in Figure 1
50 Gene fusion partners ETS genes
TMPRSS2 SLC45A3 NDRG1 Herv-K22q11.23 ERG ETV1 ETV5 ETV4
Rearranged cases 43.2% (35/81) 11.6% (10/86) 2.4% (2/85) 0.0% (0/84) 51.2% (44/86) 5.9% (5/85) 1.2% (1/86) 0.0% (0/83)
Figure 2 Representative example showing FISH images with gene rearrangement (here ERG) with different rearrangement mechanisms, (a) rearrangement
through insertion (b) rearrangement through deletion, in separate tumor foci in one case.
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rearrangements of 50 partners TMPRSS2 and SLC45A3 along
with ERG rearrangement. SLC45A3-ERG fusion could not be
confirmed in these cases by FISH, suggesting TMPRSS2-ERG
fusion and a different 30 fusion partner to SLC45A3.T w o
cases harbored TMPRSS2 and NDRG1 rearrangement with
co-occurring ERG rearrangement. In case #20, NDRG1-ERG
fusion could be confirmed by FISH. Case #2 was earlier
confirmed as a NDRG1-ERG fusion by RT–PCR in a study by
Pflueger et al
25 One case (#17) showed two ETS genes (ie
ERG and ETV1) and two 50 partners (ie TMPRSS2 and
SLC45A3) to be rearranged in the same focus, but we could
not confirm that two fusions were present in the same focus
using FISH fusions assays (Figure 4). The last case (#14)
demonstrated multiple rearrangements in different foci of the
prostate. Interestingly, all seven cases harboring multiple
rearrangements showed ERG rearrangement through inser-
tion. We implemented a novel assay using four-color in situ
hybridization to demonstrate the simultaneous rearrange-
ments in the same cells of the tumor. For this approach, we
used a case (#20) harboring TMPRSS2, NDRG1, and ERG
rearrangements to confirm simultaneous rearrangements
(Figure 3). No association was observed between harboring
Table 2 Event summary of co-occurring gene rearrangements
ERG ETV1 ETV5 ETV4 Total number
of events
TMPRSS2 35 3 0 0 38
SLC45A3 9 0 1 0 10
NDRG1 2 1 0 0 3
Total number of events 46 4 1 0
Figure 3 Simultaneous rearrangement of TMPRSS2 and NDRG1 in the same cancer nucleus demonstrated by four-color FISH. By using four differently
labeled probes, we are able to show simultaneous rearrangements of two 50 gene fusion partners within the same nucleus. Top panel shows a benign
nucleus. The first two images from the left show no rearrangement of NDRG1 and TMPRSS2, respectively. Top right image shows the merged signals of
NDRG1 and TMPRSS2 in the same nucleus. Bottom panel shows a prostate cancer nucleus with NDRG1 (left) and TMPRSS2 (middle) rearrangement. Bottom right
image shows the merged image of the two gene rearrangements within the same nucleus. This case (#20) also harbors ERG rearrangement (not shown).
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Similarly, we did not observe association between
intraindividual heterogeneity in terms of rearrangement
status and Gleason grade or stage.
DISCUSSION
The original observation that ETS fusions are mutually
exclusive
14 holds true within an individual tumor focus in the
majority of cases tested. This study confirms the observation
made by Clark et al
10 that more than one ETS rearrangement
can exist in a prostate gland. The current study also
systematically demonstrates that ETS rearrangements may
serve as clonal markers of tumors when present. However,
mutual exclusivity of ETS rearrangements does have excep-
tions. We observed that 8% of the cases harbored a
TMPRSS2-ERG gene rearrangement plus an additional gene
rearrangement within the same focus in six out of seven
cases. In these six cases, we could confirm multiple re-
arrangements present in the same cells of the tumor focus.
Using the tissue block that was used to construct the TMA
with the QD technology, we were able to visualize the
TMPRSS2 and NDRG1 rearrangements within the same
nucleus (Figure 3). Interestingly, all cases with multiple
rearrangements are characterized by ERG rearrangement
through insertion. Using the next generation RNA sequen-
cing, we have identified other examples of non-
ETS rearrangements occurring concurrently with ETS
rearrangements
26 (Pflueger and Rubin, unpublished
observations). In these cases, the rearrangements do not
appear to be recurrent but restricted to the individual case
(‘private events’). Some of these fusions may only occur in
rare subclones of tumor cells unlike the common ETS
rearrangements making them harder to detect by FISH or
other in situ methods. Future studies will be required to
determine whether these secondary rearrangements (both
ETS and non-ETS) act in a synergistic manner with the
primary molecular events to confer tumor growth advantage
or simple represent passenger events. From the DNA se-
quencing of prostate cancer (Berger et al, unpublished data),
we are also observing a multitude of other molecular muta-
tions that may also fit into a spectrum between passenger
events and driver events. Taken together, the complexity of
mutations and rearrangements should provide insight into
prostate cancer disease progression. Other translocation
tumors such as myeloma have been shown to harbor sec-
ondary translocations.
27
The incidence of ETS rearrangement found in this study is
in agreement with prior studies.
7,15 We confirmed SLC45A3
as the second most common 50 gene partner, with a 12%
rearrangement frequency in this cohort, similar to the 10%
SLC45A3 rearrangement frequency observed in a large cohort
(n¼553) from Berlin, Germany.
Many investigators have previously reported that when
the ERG rearrangements occur, all of the tumor cells within a
nodule show the alteration
5,17; this suggests that this is
either an early event or possibly an event that covers a
growth advantage to the other tumor cells. We have also
recently demonstrated this by immunohistochemistry
using antibodies specific for the ERG rearrangement.
28 In
the current study, we found cases showing intrafocal
heterogeneity (ie both rearranged and non-rearranged
nuclei in the same cancer focus). We also found cases where
the same gene rearrangement showed both types of
rearrangement mechanisms (ie rearrangement through
insertion and deletion) within the same focus (Figure 5).
These findings were seen in both ETS gene rearrangements
and rearrangements of the 50 partners. Accumulating data
suggest that the TMPRSS2-ERG fusion is an early molecular
event based on the presence of the rearrangement in
high-grade PIN, animal model data, and recent data from
Attard et al,
13 showing that the circulating tumor cells either
all have the ETS rearrangement or not. In the later study, they
showed that other molecular alterations such as PTEN loss
are only seen in a subset of the circulating tumor cells.
There is emerging data suggesting a functional role of ETS
rearranged prostate cancer. However, some areas of
clarification are needed. In vitro studies differ in terms of ETS
role in cell proliferation. It has been widely shown that
overexpression of ERG,
29–31 ETV1,
32 or ETV5 leads to an
increase in cell invasion but not proliferation. Recent studies
Figure 4 Co-occurring rearrangements of the two ETS genes. In case #17, we see co-occurring rearrangement of ERG and ETV1 (red-labeled FISH probe) and
two 50 gene partners, TMPRSS2 and SLC45A3 (green-labeled FISH probe). All rearrangements were through insertion mechanism. Fusion FISH was performed
but could not identify multiple fusions within the focus. Fusion assay with SLC45A3-ERG (a), SLC45A3-ETV1 (b), and finally TMPRSS2-ETV1 (c).
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leads to mouse PIN.
29,30,32 Other studies have shown that
ERG overexpression does not lead to high-grade PIN in mice
but can lead to aggressive adenocarcinoma if in combination
with other genetic lesions (eg PTEN loss or AKT activa-
tion).
33–35 Subtle differences between the different mouse
models may explain the discrepancies in the observations.
Genetic analyses do not show an increase in genomic
instability based on ETS rearrangement status. However, the
specific types of genomic lesions do differ between
rearrangement positive and negative cancers.
36 Thus, there is
overwhelming data showing that ETS rearranged prostate
cancer are phenotypically and molecularly different from
prostate cancers lacking ETS gene rearrangements and that
they may constitute a distinct subclass of prostate cancer.
The clinical implications of having a TMPRSS2-ERG
fusion prostate cancer are still controversial.
37 Prostate cancer
specific fusions are still helpful in the diagnosis of prostate
cancer as they are highly cancer specific. In addition, similar
to PCA3,
38 the TMPRSS2-ERG fusion can be detected in
urine when present in the prostate gland. Hessels et al
39 and
Laxman et al
40 both showed that multiplexed post-DRE urine
assays searching for TMPRSS2-ERG fusion transcripts had
high specificity and therefore may be successful as a prostate
cancer screening tool. In both studies the sensitivity is low.
The theoretical sensitivity is based on the frequency of the
cancer-specific gene fusions. As demonstrated in the current
study and other reports, a number of other, albeit less
common cancer-specific gene fusions exist and would help
improve the sensitivity of such an assay. Furthermore, the list
of 50 fusion partners for ERG and other ETS family members
is expanding.
25,41
In summary, the frequencies of ETS rearrangement and 50
fusion partners in this study is similar to what has been
previously reported. This is the first study to systematically
examine multiple ETS rearrangement in multifocal prostate
cancer. Our results demonstrate an additional level of
complexity concerning the distribution of gene rearrange-
ments in prostate cancer. This is exemplified by our
observation that multiple rearrangements can exist within
one prostate gland, within the same tumor focus, and can
also occur within the same nucleus. These events need to
be further investigated to determine biological or clinical
implications.
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